Mark Sheptoff Financial Planning, LLC Harmony Biosciences Holdings, Inc. Transaction History

Mark Sheptoff Financial Planning, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$19.2 - $33.78 $7,680 - $13,512	400 New	400 $12,000
Q2 2023 Aug 10, 2023	SELL	$30.5 - $37.4 $36,600 - $44,880	-1,200 Reduced 40.0%	1,800 $63,000
Q4 2022 Feb 14, 2023	SELL	$45.4 - $60.91 $4,540 - $6,091	-100 Reduced 3.23%	3,000 $165,000
Q3 2022 Nov 08, 2022	SELL	$42.06 - $55.45 $21,030 - $27,725	-500 Reduced 13.89%	3,100 $137,000
Q2 2022 Aug 11, 2022	SELL	$33.54 - $52.15 $16,770 - $26,075	-500 Reduced 12.2%	3,600 $176,000
Q1 2022 May 12, 2022	BUY	$33.14 - $51.13 $102,734 - $158,503	3,100 Added 310.0%	4,100 $199,000
Q4 2021 Feb 11, 2022	BUY	$34.09 - $43.91 $34,090 - $43,910	1,000 New	1,000 $43,000

262

47M

119K

50K

Ticker HRMY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,161,400
Market Cap $1.73B
Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...

Get notified when there are updates to the investment portfolio of Mark Sheptoff Financial Planning, LLC, based on Form 13F filings with the SEC.

Stay updated on Mark Sheptoff Financial Planning, LLC with notifications on news.